Article
As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.
As reported by the Wall Street Journal, the FDA is seeking advice from a panel of medical experts on whether the antidepressant Cymbalta should be used as a treatment for chronic pain.
Eli Lilly & Co, the company that markets the drug, is seeking approval for the expanded use as a treatment for chronic pain conditions that would include pain caused by osteoarthritis or low back pain. Currently, the drug is also approved to treat diabetic nerve pain, fibromyalgia, and anxiety.
However, there are safety concerns associated with the drug, including possible liver damage and bleeding risks. The drug will be reviewed Thursday.